Ascentage Pharma Group International ( (HK:6855) ) has shared an announcement.
Ascentage Pharma Group International announced that the underwriters of its U.S. initial public offering have partially exercised their over-allotment option, purchasing an additional 935,144 American Depositary Shares (ADSs). This increases the total ADSs sold to 8,260,144, generating approximately $142.5 million in gross proceeds for the company. This move is expected to bolster Ascentage Pharma’s financial resources, supporting its growth strategy and enhancing its positioning in the biotechnology industry.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biotechnology company incorporated in the Cayman Islands, focusing on novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company is known for its innovative development of apoptosis-targeted drugs, aiming to meet critical unmet medical needs in both China and global markets.
YTD Price Performance: -19.58%
Average Trading Volume: 2,616,399
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$12.48B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.